Subscribe to RSS
DOI: 10.1055/s-2004-835844
© Georg Thieme Verlag KG Stuttgart · New York
Effect of Food Intake on the Bioavailability of Boswellic Acids from a Herbal Preparation in Healthy Volunteers
Publication History
Received: March 12, 2004
Accepted: August 19, 2004
Publication Date:
10 January 2005 (online)
Abstract
In this study we investigated the effects of concomitant food intake on the bioavailability of distinct boswellic acids (BAs) from the test preparation BSE-018, a dry extract from Boswellia serrata gum resin. In a randomised, open, single-dose, two-way crossover study, healthy male subjects received three capsules of BSE-018 equivalent to 786 mg dry extract of Boswellia serrata gum resin either in the fasted state or together with a standardised high-fat meal. BA plasma concentrations were analysed for up to 60 h after oral dosing by reversed phase HPLC. As compared to the fasted state (treatment A), the administration of BSE-018 concomitantly with a high-fat meal (treatment B) led to several-fold increased areas under the plasma concentration-time curves as well as peak concentrations of β-boswellic acid (βBA), 11-keto-β-boswellic acid (KβBA) and acetyl-11-keto-β-boswellic acid (AKβBA). Plasma levels of both acetyl-α-boswellic acid (AαBA) and αBA became only detectable when administered with treatment B, i. e., the high-fat meal. Accordingly, pharmacokinetic data could be calculated for βBA, KβBA and AKβBA (treatment A) and for βBA, KβBA, AKβBA, αBA, and AαBA (treatment B). For the first time these data reveal detailed kinetics of BAs after oral dosing of an extract and demonstrate a profound effect of food intake on the pharmacokinetic profile of the BAs. This finding should be very important whenever BAs would be considered for therapeutic use.
Key words
Boswellia serrata - Burseraceae - boswellic acid - pharmacokinetics - half-life - bioavailability
References
- 1 Ammon H PT, Mack T, Singh G B, Safayhi H. Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of Boswellia serrata . Planta Medica. 1991; 57 203-7
- 2 Belsner K, Büchele B, Werz U, Syrovets T, Simmet T h. Structural analysis of pentacyclic triterpenes from the gum resin of Boswellia serrata by NMR spectroscopy. Magn Reson Chem. 2003; 41 115-22
- 3 Safayhi H, Mack T, Sabieraj J, Anazodo M I, Subramanian L R, Ammon H PT. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther. 1992; 261 1143-6
- 4 Safayhi H, Sailer E R. Anti-inflammatory actions of pentacyclic triterpenes. Planta Medica. 1997; 63 487-93
- 5 Hoernlein R F, Orlikowski T h, Zehrer C, Niethammer D, Sailer E R, Simmet T h, Dannecker G E, Ammon H PT. Acetyl-11-β-keto-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I. J Pharmacol Exp Ther. 1999; 288 613-9
- 6 Syrovets T, Büchele B, Gedig E, Slupsky J R, Simmet T h. Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIα. Mol Pharmacol. 2000; 58 71-81
- 7 Heldt M R. et al . Boswellic Acids exhibit cytotoxic effects on brain tumor cells independent from 5-lipoxygenase inhibition. Naunyn-Schmiedeberg’s Arch Pharmacol. 1997; 355 (Suppl) 30
- 8 Zhao W, Entschladen F, Liu H, Niggemann B, Fang Q, Zaenker K S, Han R. Boswellic acid acetate induces differentiation and apotosis in highly metastatic melanoma and fibrosarcoma cells. Cancer Detect Prev. 2003; 27 67-75
- 9 Gupta I, Gupta V, Parihar A, Gupta S, Ludtke R, Safayhi H, Ammon H P. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res. 1998; 3 511-4
- 10 Sander O, Herborn G, Rau R. Ist H15 (Harzextrakt von Boswellia serrata, ”Weihrauch”) eine sinnvolle Ergänzung zur etablierten medikamentösen Therapie der chronischen Polyarthritis? Ergebnisse einer doppelblinden Pilotstudie. Z Rheumatol. 1998; 57 11-6
- 11 Janssen G, Bode U, Breu H, Dohrn B, Engelbrecht V, Gobel U. Boswellic acids in the palliative therapy of children with progressive or relapsed brain tumors. Klin Padiatr. 2000; 212 189-95
- 12 Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R. Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol. 2001; 39 11-7
- 13 Schweizer S, von Brocke A F, Boden S E, Baer E, Ammon H P, Safayhi H. Workup-dependent formation of 5-lipoxygenase inhibitory boswellic acid analogues. J Nat Prod. 2000; 63 1058-61
- 14 Ganzera M, Khan I A. A reversed phase high performance liquid chromatography method for the analysis of boswellic acids in Boswellia serrata . Planta Medica. 2001; 67 778-80
- 15 Tawab M A, Kaunzinger A, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. Development of a high-performance liquid chromatographic method for the determination of 11-keto-β-boswellic acid in human plasma. J Chromatogr B. 2001; 761 221-7
- 16 Büchele B, Sterk V, Zugmaier W, Belsner K, Simmet T h. Analysis of boswellic acids in human plasma after oral administration of a boswellic acid containing drug. Naunyn-Schmiedberg’s Arch Pharmacol. 2000; 361 (Suppl) 487
- 17 Büchele B, Zugmaier W, Simmet T h. Analysis of pentacyclic triterpenic acids from frankincense gum resins and related phytopharmaceuticals by high-performance liquid chromatography. Identification of lupeolic acid, a novel pentacyclic triterpene. J Chromatography B. 2003; 791 21-30
- 18 Büchele B, Simmet T h. Analysis of 12 different pentacyclic triterpenic acids from frankincense in human plasma by high-performance liquid chromatography and photodiode array detection. J Chromatography B. 2003; 795 355-62
- 19 Safayhi H, Sailer E R, Ammon H PT. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-β-boswellic acid. Mol Pharmacol. 1995; 47 1212-6
- 20 Park Y S, Lee J H, Bondar J, Harwalkar J A, Safayhi H, Golubic M. Cytotoxic action of acetyl-11-keto-β-boswellic acid (AKBA) on menigioma cells. Planta Medica. 2002; 68 397-401
Dr. Thomas Simmet
Department of Pharmacology of Natural Products and Clinical Pharmacology
University of Ulm
Helmholtzstr. 20
89081 Ulm
Germany
Fax: +49-731-500-24280
Email: thomas.simmet@medizin.uni-ulm.de